Literature DB >> 27913284

Cardiac proteasome functional insufficiency plays a pathogenic role in diabetic cardiomyopathy.

Jie Li1, Wenxia Ma2, Guihua Yue3, Yaoliang Tang2, Il-Man Kim2, Neal L Weintraub2, Xuejun Wang4, Huabo Su5.   

Abstract

BACKGROUND: Diabetic cardiomyopathy is a major risk factor in diabetic patients but its pathogenesis remains poorly understood. The ubiquitin-proteasome system (UPS) facilitates protein quality control by degrading unnecessary and damaged proteins in eukaryotic cells, and dysfunction of UPS is implicated in various cardiac diseases. However, the overall functional status of the UPS and its pathophysiological role in diabetic cardiomyopathy have not been determined. METHODS AND
RESULTS: Type I diabetes was induced in wild-type and transgenic mice expressing a UPS functional reporter (GFPdgn) by injections of streptozotocin (STZ). STZ-induced diabetes progressively impaired cardiac UPS function as evidenced by the accumulation of GFPdgn proteins beginning two weeks after diabetes induction, and by a buildup of total and lysine (K) 48-linked polyubiquitinated proteins in the heart. To examine the functional role of the UPS in diabetic cardiomyopathy, cardiac overexpression of PA28α (PA28αOE) was used to enhance proteasome function in diabetic mouse hearts. PA28αOE diabetic mice displayed exhibited restoration of cardiac UPS function, as demonstrated by the diminished accumulation of GFPdgn and polyubiquitinated proteins. Moreover, PA28αOE diabetic mice exhibited reduced myocardial collagen deposition, decreased cardiomyocyte apoptosis, and improved cardiac systolic and diastolic function.
CONCLUSION: Impairment of cardiac UPS function is an early event in STZ-induced diabetes. Overexpression of PA28α attenuates diabetes-induced proteotoxic stress and cardiomyopathy, suggesting a potential therapeutic role for enhancement of cardiac proteasome function in this disorder. Copyright Â
© 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Diabetic cardiomyopathy; PA28α; Proteasome; Ubiquitin

Mesh:

Substances:

Year:  2016        PMID: 27913284      PMCID: PMC5316366          DOI: 10.1016/j.yjmcc.2016.11.013

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  51 in total

Review 1.  Degradation of oxidized proteins by the 20S proteasome.

Authors:  K J Davies
Journal:  Biochimie       Date:  2001 Mar-Apr       Impact factor: 4.079

2.  Immunoproteasomes preserve protein homeostasis upon interferon-induced oxidative stress.

Authors:  Ulrike Seifert; Lukasz P Bialy; Frédéric Ebstein; Dawadschargal Bech-Otschir; Antje Voigt; Friederike Schröter; Timour Prozorovski; Nicole Lange; Janos Steffen; Melanie Rieger; Ulrike Kuckelkorn; Orhan Aktas; Peter-M Kloetzel; Elke Krüger
Journal:  Cell       Date:  2010-08-20       Impact factor: 41.582

3.  Tau-driven 26S proteasome impairment and cognitive dysfunction can be prevented early in disease by activating cAMP-PKA signaling.

Authors:  Natura Myeku; Catherine L Clelland; Sheina Emrani; Nikolay V Kukushkin; Wai Haung Yu; Alfred L Goldberg; Karen E Duff
Journal:  Nat Med       Date:  2015-12-21       Impact factor: 53.440

4.  Optimal determination of heart tissue 26S-proteasome activity requires maximal stimulating ATP concentrations.

Authors:  Saul R Powell; Kelvin J A Davies; Andras Divald
Journal:  J Mol Cell Cardiol       Date:  2006-11-30       Impact factor: 5.000

5.  The ubiquitin-proteasome system contributes to the inflammatory injury in ischemic diabetic myocardium: the role of glycemic control.

Authors:  Raffaele Marfella; Clara Di Filippo; Michele Portoghese; Mario Siniscalchi; Simone Martis; Franca Ferraraccio; Salvatore Guastafierro; Gianfranco Nicoletti; Michelangela Barbieri; Antonino Coppola; Francesco Rossi; Giuseppe Paolisso; Michele D'Amico
Journal:  Cardiovasc Pathol       Date:  2009-01-14       Impact factor: 2.185

Review 6.  Diabetic cardiomyopathy revisited.

Authors:  Sihem Boudina; E Dale Abel
Journal:  Circulation       Date:  2007-06-26       Impact factor: 29.690

Review 7.  Functional alterations of cardiac proteasomes under physiological and pathological conditions.

Authors:  Osamu Tsukamoto; Tetsuo Minamino; Masafumi Kitakaze
Journal:  Cardiovasc Res       Date:  2009-08-14       Impact factor: 10.787

Review 8.  An overview of the crosstalk between inflammatory processes and metabolic dysregulation during diabetic cardiomyopathy.

Authors:  Xavier Palomer; Laia Salvadó; Emma Barroso; Manuel Vázquez-Carrera
Journal:  Int J Cardiol       Date:  2013-08-06       Impact factor: 4.164

9.  Diabetic downregulation of Nrf2 activity via ERK contributes to oxidative stress-induced insulin resistance in cardiac cells in vitro and in vivo.

Authors:  Yi Tan; Tomonaga Ichikawa; Jinqing Li; Qiusheng Si; Huaitao Yang; Xiangbai Chen; Curtis S Goldblatt; Colin J Meyer; Xiaokun Li; Lu Cai; Taixing Cui
Journal:  Diabetes       Date:  2011-02       Impact factor: 9.461

10.  Enhancement of proteasome activity by a small-molecule inhibitor of USP14.

Authors:  Byung-Hoon Lee; Min Jae Lee; Soyeon Park; Dong-Chan Oh; Suzanne Elsasser; Ping-Chung Chen; Carlos Gartner; Nevena Dimova; John Hanna; Steven P Gygi; Scott M Wilson; Randall W King; Daniel Finley
Journal:  Nature       Date:  2010-09-09       Impact factor: 49.962

View more
  16 in total

1.  The Calcineurin-TFEB-p62 Pathway Mediates the Activation of Cardiac Macroautophagy by Proteasomal Malfunction.

Authors:  Bo Pan; Jie Li; Nirmal Parajuli; Zongwen Tian; Penglong Wu; Megan T Lewno; Jianqiu Zou; Wenjuan Wang; Lynn Bedford; R John Mayer; Jing Fang; Jinbao Liu; Taixing Cui; Huabo Su; Xuejun Wang
Journal:  Circ Res       Date:  2020-05-05       Impact factor: 17.367

Review 2.  Priming the Proteasome to Protect against Proteotoxicity.

Authors:  Xuejun Wang; Hongmin Wang
Journal:  Trends Mol Med       Date:  2020-03-26       Impact factor: 11.951

Review 3.  Interrelationship between diabetes mellitus and heart failure: the role of peroxisome proliferator-activated receptors in left ventricle performance.

Authors:  Evangelos Oikonomou; Konstantinos Mourouzis; Petros Fountoulakis; Georgios Angelos Papamikroulis; Gerasimos Siasos; Alexis Antonopoulos; Georgia Vogiatzi; Sotiris Tsalamadris; Manolis Vavuranakis; Dimitris Tousoulis
Journal:  Heart Fail Rev       Date:  2018-05       Impact factor: 4.214

Review 4.  Proteasome biology and therapeutics in cardiac diseases.

Authors:  Sanket Kumar Shukla; Khadija Rafiq
Journal:  Transl Res       Date:  2018-09-28       Impact factor: 7.012

Review 5.  Diabetic cardiomyopathy: molecular mechanisms, detrimental effects of conventional treatment, and beneficial effects of natural therapy.

Authors:  Brahmanaidu Parim; V V Sathibabu Uddandrao; Ganapathy Saravanan
Journal:  Heart Fail Rev       Date:  2019-03       Impact factor: 4.214

6.  Vascular Spasm: A Newly Unraveled Cause for Cardiovascular Adversity of Proteasome Inhibition.

Authors:  Xuejun Wang
Journal:  EBioMedicine       Date:  2017-06-13       Impact factor: 8.143

Review 7.  Can the onset of heart failure be delayed by treating diabetic cardiomyopathy?

Authors:  Anna Marcinkiewicz; Stanisław Ostrowski; Józef Drzewoski
Journal:  Diabetol Metab Syndr       Date:  2017-04-04       Impact factor: 3.320

Review 8.  The Diabetic Cardiomyopathy: The Contributing Pathophysiological Mechanisms.

Authors:  Teresa Salvatore; Pia Clara Pafundi; Raffaele Galiero; Gaetana Albanese; Anna Di Martino; Alfredo Caturano; Erica Vetrano; Luca Rinaldi; Ferdinando Carlo Sasso
Journal:  Front Med (Lausanne)       Date:  2021-06-30

9.  Osteocrin, a novel myokine, prevents diabetic cardiomyopathy via restoring proteasomal activity.

Authors:  Xin Zhang; Can Hu; Xiao-Pin Yuan; Yu-Pei Yuan; Peng Song; Chun-Yan Kong; Teng Teng; Min Hu; Si-Chi Xu; Zhen-Guo Ma; Qi-Zhu Tang
Journal:  Cell Death Dis       Date:  2021-06-16       Impact factor: 8.469

10.  Ubiquitin-protein ligase E3a (UBE3A) as a new biomarker of cardiac hypertrophy in cell models.

Authors:  Kai-Chun Cheng; Yingxiao Li; Wei-Ting Chang; Zhih-Cherng Chen; Juei-Tang Cheng; Cheng-Chia Tsai
Journal:  J Food Drug Anal       Date:  2018-08-24       Impact factor: 6.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.